What is DayTwo?
DayTwo operates at the intersection of biotechnology and digital health, leveraging advanced microbiome analysis to deliver personalized nutrition insights. By utilizing individual biometrics and lifestyle data, the platform enables users to maintain optimal blood glucose levels, effectively addressing metabolic health challenges. Founded in 2015, the company is built upon foundational research conducted by Prof. Eran Segal and Prof. Eran Elinav at the Weizmann Institute of Science. This scientific pedigree provides a robust competitive moat, allowing DayTwo to offer actionable, data-driven health interventions that distinguish it from generic wellness applications. The company's market position is further bolstered by its ability to integrate complex biological data into user-friendly, enterprise-grade health solutions.
How much funding has DayTwo raised?
DayTwo has raised a total of $85.4M across 6 funding rounds:
Series A
$12M
Series B
$31M
Other Financing Round
$5M
Debt
$150K
Debt
$254K
Unspecified
$37M
Series A (2017): $12M with participation from Johnson & Johnson and Seventure Partners
Series B (2019): $31M led by Seventure Partners, aMoon, Ofek Ventures, and Johnson & Johnson
Other Financing Round (2019): $5M, investors not publicly disclosed
Debt (2020): $150K featuring PPP
Debt (2021): $254K backed by PPP
Unspecified (2021): $37M with participation from Micron Ventures, La’maison Fund, and Poalim Capital Markets
Key Investors in DayTwo
Seventure Partners
Seventure Partners is an active partner of innovative companies in the fields of digital technologies and life sciences, focusing on health, nutrition, and sustainable blue economy initiatives.
Johnson & Johnson
A global leader in healthcare, Johnson & Johnson invests in transformative technologies that align with its mission to improve human health outcomes through science and innovation.
Poalim Capital Markets
Poalim Capital Markets provides institutional investors and corporations with access to financial solutions that support value formation and strategic growth in global markets.
What's next for DayTwo?
With the recent influx of capital, DayTwo is well-positioned to accelerate its commercial expansion and deepen its clinical validation efforts. The strategic focus will likely shift toward enhancing its digital health ecosystem, potentially through expanded partnerships with healthcare providers and insurance entities seeking to reduce the long-term costs associated with metabolic disorders. As the company matures, the emphasis will remain on scaling its proprietary algorithms and broadening its reach within the precision medicine market. By leveraging its strong investor backing, DayTwo aims to solidify its role as a leader in the personalized nutrition space, driving sustainable growth through continued innovation and strategic market penetration.
See full DayTwo company page
